Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

Saturday, April 26, 2014

Here is the Story of One's Man's Diagnosis with MS and his struggle to Rise from the Depths of Despair


Normally, I do not post about books being written but after meeting David and speaking with him I feel his story is quite empowering.

David and I are the same age. I just wished that I had the umph to do what he does, to keep his body strong.  Although, LOL - My Mind is Mighty...

Read more, here: http://www.themsbodybuildingchallenge.com/

David's Body Building Challenge is NOW Expanding to The MS Fitness Challenge





Disclaimer: Neither Stu's Views & MS News nor MS Views and News, had any view or input into the writing of this book nor are we earning anything from "David's Goliath" sales


……..


To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information

Thank you    
…………………….
.

ActiveMSers - a website designed to help, motivate and inspire those with multiple sclerosis

Dave Bexfield, 45, is the founder of www.ActiveMSers.org, a website designed to help, motivate and inspire those with multiple sclerosis to stay as active as possible—physically, intellectually and socially—regardless of physical limitations. Established when Dave was diagnosed in 2006, ActiveMSers has helped hundreds of thousands of people with MS from around the world through its encouraging website, blogTwitter feedFacebook page, and discussion forum
Its motto: Be active, stay fit and keep exploring! 

ActiveMSers is designed to help, motivate, and inspire those with multiple sclerosis to stay as active as possible—physically, intellectually, and socially—regardless of physical limitations.  > Unbiased reviews and tests of gear
ActiveMSers reviews, tests and compares MS aids including cooling vests, trekking poles, forearm crutches, medication coolers, and more.
> Expert advice on multiple sclerosis exercises
With input from physical therapists and MS experts, ActiveMSers will show you how to maximize mobility through exercise and stretching.
> 100s of helpful tips and tricks on living with MS
Find tips about living with multiple sclerosis, from how to deal with heat to coping with fatigue to traveling the world. Get motivated!
> Forum, blog, and free newsletter
Connect with fellow MSers for advice and tips through our web forum. Learn how to cope through our blog. Sign up for our free e-newsletter.


An Albuquerque, NM, resident and longtime professional writer, Dave’s efforts have been championed by The New York Times, featured in a half-page promotion in the Wall Street Journal and he has been profiled often in local media. His video recapping his groundbreaking NIH-sponsored stem cell transplant won fan favorite at the American Academy of Neurology 2011 Neuro Film Festival and was used to lobby for health insurance reform on Capitol Hill. And this past August one of his travel stories won the international New Mexico True ultimate insider contest thanks to the support of dedicated members. Armed with attitude and a pair of forearm crutches, Dave continues to travel the world with his wife of 20 years, Laura.


……..


To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------

Thank you    
…………………….
.

EMD Serono Presents New Data on Rebif® (interferon beta-1a) and Advancing MS Pipeline at AAN Annual Meeting

April 25, 2014

ROCKLAND, Mass., April 25, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.
Data from 14 study assessments presented by EMD Serono or its affiliate, Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, will focus on Rebif® (interferon beta-1a), as well as three pipeline candidates:
  • Ceralifimod (ONO-4641) (S1P receptor agonist), an investigational oral compound being evaluated in a Phase II trial for relapsing-remitting MS.
  • ATX MS-1467, an investigational compound being evaluated in a Phase I trial for MS.
  • Plovamer Acetate (PI-2301), a second-generation peptide copolymer being evaluated in a Phase II clinical trial for MS. Plovamer Acetate is designed to bind to major histocompatibility complex (MHC) class II allelic variants associated with MS, with the aim of promoting regulatory effects in the immune system. 
"The data to be presented during the AAN meeting continue to advance our understanding of the important clinical effects of Rebif and demonstrate progress with our three pipeline candidates," said Thorsten Eickenhorst, Chief Medical Officer, EMD Serono. "Our company's scientific commitment to MS includes more than 20 years of clinical experience with Rebif and we continue to work to develop innovative treatment options and solutions for those living with MS."
The following abstracts have been accepted for presentation at the 66th AAN Annual Meeting:
Rebif (interferon beta-1a)
  • Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a  (Poster P3.146 Session III;  Tuesday, April 29, 2014)
  • Correlations between Immunological Biomarkers and Conventional and Advanced MRI Measures Following Interferon Beta-1a Treatment for Relapsing-Remitting Multiple Sclerosis (Poster P3.147 Session III; Tuesday, April 29, 2014)
  • Early and Consistent Reduction in Relapses among Patients with Relapsing-Remitting Multiple Sclerosis Receiving Subcutaneous Interferon Beta-1a: A Post-Hoc Analysis of PRISMS Data (Poster P3.182 Session III; Tuesday, April 29, 2014)
  • Assessing a Scoring System to Predict Disease Activity in Patients with Multiple Sclerosis: Post Hoc Analyses of Data from Clinical Trials of Subcutaneous Interferon Beta-1a (Poster P3.178 Session III; Tuesday, April 29, 2014)
  • Changes in Immunological Biomarkers in Patients with Relapsing–Remitting Multiple Sclerosis Treated with Interferon Beta-1a (Poster P4.132 Session IV; Wednesday, April 30, 2014)
  • Associations Between Changes in Ferritin Levels and  Susceptibility-Weighted Imaging Filtered Phase in Patients with Relapsing-Remitting Multiple Sclerosis over Six Months Therapy with Interferon Beta-1a   (Poster P6.115, Session VI; Thursday, May 1, 2014)
  • Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240, Session VII; Thursday, May 1, 2014)
  • Adherence to, and Effectiveness of, Treatment with Subcutaneous Interferon Beta-1a in Relapsing Multiple Sclerosis Patients using RebiSmart™ for Self-Injection: Final Results of the One-Year International, Observational SMART Study (P7.219, Session VII; Thursday, May 1, 2014) 


……..

To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------

Thank you    
…………………….
.

Stem cells from bone marrow are being investigated as possible treatments for Multiple Sclerosis

Stem cells from bone marrow are being investigated as possible treatments for Multiple Sclerosis. 
Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

5trialstaggedasMultipleSclerosis

  • Stem Cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)Location: UK
    Overview:This trial is investigating the effect of the patient’s own mesenchymal stem cells in multiple sclerosis (MS). The trial is being conducted by the Imperial College Hospital in London expects to enrol 13 patients between January 2013 and July 2015. Bone marrow stem cells will be harvested from all the participants and expanded in the laboratory over 52 days. Participants will be randomly assigned into treatment or control groups. Those in the control group will receive standard treatment and a placebo injection, whilst those in the treatment group will receive their own expanded cells. Neither the patients, nor the doctors will know which group they are in. Participants will be monitored for complications, as well changes in the number of sclerotic lesions in the brain. After 24 weeks patients in the control group will receive their expanded stem cells and both groups monitored again as in the first 24 weeks.
    Link to Clinical Registry
    Trial Design:Safety and Efficacy Study

    Status:Open - Recruiting

    Stem Cell:Adult Bone Marrow Stem Cells
  • Own Mesenchymal Stem Cells for Multiple Sclerosis PatientsLocation: Denmark
    Overview:This trial aims is to determine the effect of the patient's own MSCs on cerebral inflammation in Multiple Sclerosis. The trial is being conducted by the Danish Blood Bank in conjunction with the Danish Multiple Sclerosis Society. The trial commenced in June 2012 and seeks to enrol 25 patients. Participants will be randomly divided into two groups. One group will receive mesenchymal stem cells, from their own bone marrow, intravenously (initial experimental group). This group will be monitored for 24 weeks in which MRI scans will be used to monitor lesions. The remaining subjects will receive the conventional therapy for Multiple Sclerosis and then after 24 weeks, they receive a similar mesenchymal stem cell infusion and monitored by MRI for a further 24 weeks. During this time the initial experimental group will receive only conventional therapy. This is a randomised, controlled, double blinded, and double group crossover clinical trial. No end date has been set for this trial.
    Link to Clinical Registry
    Trial Design:Therapeutic intervention

    Status:Open - Recruiting

    Stem Cell:Adult Bone Marrow Stem Cells
  • Mesenchymal Stem Cells for Multiple SclerosisLocation: Sweden
    Overview:This trial aims to investigate the effect of stem cells from the patient's own bone marrow in treating multiple sclerosis. The trial is being conducted by the Karolinska Institute and the Karolinska University Hospital Solna in Stockholm and proposes to recruit 15 subjects between February 2013 and December 2015. Participants will be divided into two groups. The first group will receive an injection of their own bone marrow stem cells at the beginning of the trial. The second group will receive the injection of their own stem cells 24 weeks later. All participants will be monitored for complications and changes in clinical condition at our-week intervals for 48 weeks.
    Link to Clinical Registry
    Trial Design:Safety and Efficacy Study

    Status:Open - Recruiting

    Stem Cell:Adult Bone Marrow Stem Cells
  • Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed with Multiple SclerosisLocation: Spain
    Overview:This trial aims to evaluate the use of stem cells from the patient's own bone marrow in treatment of Multiple Sclerosis. The trial is being sponsored by Fundación Pública Andaluza Progreso y Salud and is being conducted at three University hospitals in Spain. They propose to recruit 30 patients between May 2012 and November 2014. All participants will have bone marrow stem cells harvested prior to commencement of the trial. Being a crossover study the subjects will be divided into two groups. The first group will receive the stem cell injection on the first day, while the second group will receive a placebo infusion. After 180 days, the second group will receive the stem cell injection and the first group a placebo injection. All participants will be monitored for complications following the transfusion and changes in clinical condition for one year.
    Link to Clinical Registry
    Trial Design:Safety and Efficacy Study

    Status:Open - Recruiting

    Stem Cell:Adult Bone Marrow Stem Cells
  • A Single Centre Phase II Study Of Haematopoietic Stem Cell Transplantation for Severe Auto-Immune DiseasesLocation: Australia
    Overview:This trial is evaluating the use of combining immunosuppression and the patient's bone marrow stem cells in patients with serious diseases of the immune system which have not responded to conventional treatments. The trial is being conducted at St Vincent's Hospital in Sydney and began recruiting patients in March 2011 with plans to recruit 30 subjects by December 2015. The conditions being investigated in the trial include Scleroderma, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), vasculitis, Crohn's disease and Behcet's disease. Participants will be given Granulocyte Colony Stimulating Factor (G-CSF) to stimulate the bone marrow into releasing stem cells, which will then be harvested from the blood of each participant. The patients will then undergo a course of intensive chemotherapy and/or immunotherapy depending on the individual condition after which they will receive an infusion of their own stem cells. Participants will be monitored for complications and assessed for changes in their clinical condition.
    Link to Clinical Registry
    Trial Design:Observational Study

    Status:Open - Recruiting

    Stem Cell:Adult Bone Marrow Stem Cells
Article Source found here
……..



…………………….
.

STEM CELL CLINICAL TRIALS around the WORLD

There are over 200 registered clinical trials currently underway around the world investigating the role that stem cells may play in the various systems of the human body. By using the menu on the left of this screen, you can find out more about the clinical trials for the condition you are interested in.
To use this resource, simply select the condition you are interested in from the categories displayed in the menu. For example, if you are interested in trials for Macular Degeneration, then select 'Vision loss' and 'Macular Degeneration' from the drop down menu. If the condition you are interested in is not listed, please use the search function on the US NIH Clinical Trials website.
This website provides information about current or recently completed stem cell clinical trials but to find out more about each trial click on the 'Link to Clinical Registry' button. You can also click here to see a summary of the stem cell clinical trials in Australia.

It is important to remember that just because a treatment is being evaluated as part of a clinical trial, that does not make it a proven safe and effective therapy. These trials are experimental. Visit What are clinical trials? to learn more.

Please use this listing for your research, but continue to speak to your treating Australian doctors for independent advice on what is best for you.
The listed trials have been sourced from clinical trials registries including the ANZCTRNIHChineseEuropean Union and World Health Organization. These websites remain the best place to obtain the most up to date information on clinicial trials.

We would like to thank Dr Alexey Bersenev from 
Cell Trials for sharing his database and acknowledge the support for this site provided by the Australian Government Department of Industry, Innovation, Climate Change, Science, Research and Tertiary Education.
Article Source found here

……..


To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------

Thank you    
…………………….
.

an MS patient's Passion for Feeling as best he can...

A desire to Tempt Fate Once Again . . .

New blog post from Jon Chandonnet 

Apr 25, 2014 10:30 pm


Two and a half years ago, I began working with a trainer to strengthen my core. I had been focused on writing for the previous four years. All that sitting, combined with the neurological impacts of MS, lead to my core’s weakening.

You may react by saying, “Sorry to hear that, MS is a vicious disease.”

Or you may react by saying, “Jon, that’s too bad, but you know what the disease can do. It’s up to you, in concert with the available MS therapies, to stem the tide of the disease.”
I understand both responses.

When I decided to begin working with a trainer, the book had entered the editing phase, so I had some extra time and decided to tempt fate. I wanted to try and alter the disease’s impact on my body one more time. Maybe the transformation I had experienced seven years earlier, through the diet and lifestyle shift, was a fluke? Maybe it was easier to change the body as a thirty-five year old than it was in my early forties? Maybe the clock had expired?

I didn’t give much thought to whether it was possible or whether my body would respond. I didn’t care. I wanted to improve my core strength and maybe reduce the stiffness and soreness I felt each morning that lingered as I moved through the day.

Last Year

After working with a trainer for eighteen months, my core strength improved to the point where it felt more natural to run again, and my body was less sore and stiff in the morning. My definition of running again means to be able to sustain the effort for more than a hundred feet. That hadn’t been possible since my return from the diet and detox center in the fall of 2005.

Last March, I made a video about running on the beach between lifeguard stands. I continued on that path for two months until I had to stop. My ego was in control, not my body. I had to take a step back. I needed to isolate my left leg and improve its strength, responsiveness, and fluidity before I could sustain the effort of running. I have done that over the last year, and my body now feels ready to take on the goal.

Can I tempt Fate Again?

This is about more than my goal to run again. My ego needs to sit this one out. It’s about listening to my body and taking action in the sequence that will allow me to naturally achieve what I want. Can I tempt fate once again? I think I can, and its that conviction that will serve me well in this latest pursuit.

Is there an area in your life where it will be beneficial to tune into your intuition to make what you want to happen more naturally?

CLICK HERE TO COMMENT ON THIS POST




…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------

Thank you    
…………………….
.

Friday, April 25, 2014

Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network

A team led by the Accelerated Cure Project for Multiple Sclerosis (ACP) has been approved for a funding award by the Patient-Centered Outcomes Research Institute (PCORI) to create the Multiple Sclerosis Patient-Powered Research Network (MS-PPRN). The MS-PPRN is one of 29 health data networks that were approved for a total of $93.5 million from PCORI to form the PCORnet: the National Patient-Centered Clinical Research Network, a new national resource that aims to boost the efficiency of health research.
ACP will build on its existing network of more than 3,200 participants, 60 research teams, and MS specialty clinics around the country to create a national patient-powered research network for MS in partnership with the Complex Adaptive Systems Initiative at Arizona State University and Feinstein Kean Healthcare. The MS-PPRN will feature patient-centric governance and will be supported by an integrated IT and communications platform featuring an ADA-compliant, patient-driven and controlled portal (iConquerMS™) that can be accessed regardless of geographical location and healthcare provider.
"The MS Patient-Powered Research Network is a ground-breaking initiative that will help to drive research to end MS forever," said Timothy Coetzee, Ph.D., Chief Advocacy, Services, and Research Officer for the National Multiple Sclerosis Society.
"We are extremely pleased that PCORI is funding the Accelerated Cure Project's program to create the MS Patient-Powered Research Network," said Edward Abrahams, Ph.D., President of the Personalized Medicine Coalition. "We believe such programs comprise a major cornerstone for a new era in which broad-based patient engagement that recognizes individual variation and productive usage of data will lead to faster discoveries and improved care for patients."
The iConquerMS™ portal will give patients the opportunity to provide health-related, demographic, and electronic health record (EHR) information that can be shared in a de-identified fashion with researchers who are investigating topics that are important to patients, such as comparative effectiveness of therapeutic agents. The MS-PPRN will be fully integrated with the Clinical Data Research Networks and the Coordinating Center of PCORnet.
Patients will also have the option of contributing biological samples through home-based collection or local laboratories to support biomarker research in MS. Additionally, educational content about the nature and practice of research, information about the participant cohort and studies supported by the MS-PPRN, and direct communications with researchers via the portal will provide more knowledge about MS research and allow patients to contribute their own ideas.
ACP's 18-month goal for enrollment in the MS-PPRN is 20,000 people with MS (5% of the estimated MS population in the United States), starting with the 3,200 participants in the current repository network. Outreach will be made through ACP's existing participant and supporter base, its network of top-tier MS clinics, other MS clinics and community neurologists, highly cooperative MS advocacy organizations who have agreed to invite their members, and social media and other communications channels.
"We congratulate ACP and the MS-PPRN team on receiving this award and look forward to working with them on this effort to help improve the quality of life for those affected by MS," said Doug Franklin, President & CEO of the Multiple Sclerosis Association of America and President of the MS Coalition, a collaborative network of independent MS organizations.
Continue reading of the ACP accomplishment found here

……..


To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------
Donate Now Please - Click here
Thank you    
…………………….
.

Wednesday, April 23, 2014

Currently we have over 7700 Signatures for Lemtrada Petition which is closing on April 30th

We seek an FDA reversal on their December 30, 2013 decision to NOT approve Sanofi’s Lemtrada, a Multiple Sclerosis Treatment. Patients needs this Medication-option Approved
There are currently 7,770 signatures

PETITION BACKGROUND Thousands of Multiple Sclerosis patients are getting worse each day, when currently used medications are not working for them or their body refuses to accept the medication. 

Another Option is needed and this Option Should be Lemtrada 

The FDA on December 30, 2013 Denies the use of Lemtrada for MS Patients. THIS was A sad day for people with more active Multiple Sclerosis. 

Lemtrada has been approved worldwide, but not good enough for us it seems, in the USA. 

We are more than 400,000 strong (living with MS) in the USA 
WE NEED YOUR VOTE to give another OPTION to those that Can benefit from this medication; hoping to keep them from severe disability. 

YES, WE NEED YOUR VOTE. 
Also we need you to write directly. WE NEED YOU TO send emails. – 
We need this request to go Viral -- 

In the middle of March, we submitted 5001 signatures to the FDA by postal mail and via email.


After we close the petition of April 30th, we will submit the final numbers
THIS IS why, for those that have not yet signed this petition, we ask you to consider again, asking the FDA about CHOICE... 
Providing another Choice

CLICK: 














…………………….
.

Data from Genzyme's Multiple Sclerosis Franchise Featured at AAN

- Aubagio(R) and Lemtrada(TM) Results To Be Highlighted -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 22, 2014-- 
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that 18 poster and oral presentations featuring Aubagio(R) (teriflunomide) and Lemtrada(TM) (alemtuzumab) will be presented during the 66th American Academy of Neurology (AAN) Annual Meeting to be held in Philadelphia, April 26 -- May 3, 2014.
"As we continue to expand our global footprint in MS with product launches planned in more than 30 countries this year, we are proud to highlight the breadth and depth of our clinical development programs for Aubagio and Lemtrada at AAN," said David Meeker, President and CEO, Genzyme. "These new data will help to build a deeper understanding of MS and Genzyme's treatments, and demonstrate our long-term commitment to meeting the needs of people living with MS."
Presentations on Aubagio and Lemtrada at AAN are as follows, along with information about the Genzyme Corporate Therapeutic Update and Brain Health Fair sponsorship.
Aubagio:
   -- TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients 
      with First Clinical Episode Consistent With Multiple Sclerosis (Clinical 
      Trials Plenary Session; May 2; 12:00 -- 1:30 p.m. EDT) 
 
   -- Teriflunomide Does Not Significantly Affect Primary and Memory Antibody 
      Responses to a Viral Antigen in Mice (Poster Session I -- P1.215; April 
      28; 3:00 p.m. EDT) 
 
   -- Teriflunomide Treatment Is Not Associated With Increased Risk of 
      Infections: Pooled Data From the Teriflunomide Development Program 
      (Poster Session II -- P2.194; April 29; 7:30 a.m. EDT) 
 
   -- Pooled Safety Data From Four Placebo-Controlled Teriflunomide Studies 
      (Poster Session II -- P2.203; April 29; 7:30 a.m. EDT) 
 
   -- Teriflunomide: Non-Clinical Evaluation Demonstrates No Effect On Sperm 
      DNA or Male Fertility (Poster Session II -- P2.233; April 29; 7:30 a.m. 
      EDT) 
 
   -- Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms 
      of Multiple Sclerosis: Update of the TEMSO Extension Trial (Poster 
      Session III -- P3.150; April 29; 3:00 p.m. EDT) 
 
   -- Patients Free of Clinical MS Activity in TEMSO and TOWER: Pooled Analyses 
      of Two Phase 3 Placebo-Controlled Trials (Poster Session III -- P3.164; 
      April 29; 3:00 p.m. EDT) 
 
   -- Updated Pregnancy Outcomes in Patients and Partners of Patients in the 
      Teriflunomide Clinical Trial Program (Poser Session IV -- P4.161; April 
      30; 7:30 a.m. EDT) 
 
   -- Estimating the Onset of Efficacy With Teriflunomide in Patients With 
      Relapsing Forms of Multiple Sclerosis (Poster Session VII -- P7.214; May 
      1; 3:00 p.m. EDT) 

Lemtrada:
-- Treatment with Anti-mouse CD52 Antibody Is Associated with Preservation
      of Myelin and Maintenance of Axonal Conduction in the MOG-induced EAE 
      Mouse Model (Poster Session I -- P1.220; April 28; 3:00 p.m. EDT) 
 
   -- Anti-murine CD52 Antibody Treatment Does Not Adversely Affect the 
      Migratory Ability of Immune Cells (Poster Session I -- P1.222; April 28; 
      3:00 p.m. EDT) 
 
   -- Successful Detection and Management of Immune Thrombocytopenia in 
      Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple 
      Sclerosis (Poster Session II -- P2.198; April 29; 7:30 a.m. EDT) 
 
   -- Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab 
      for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the 
      CARE-MS Studies (Poster Session II -- P2.199; April 29; 7:30 a.m. EDT) 
 
   -- Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in 
      Patients With Relapsing-remitting Multiple Sclerosis in the Core and 
      Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (Poster 
      Session II -- P2.201; April 29; 7:30 a.m. EDT) 
 
   -- Alemtuzumab Has Similar Efficacy and Safety in Active Relapsing-Remitting 
      Multiple Sclerosis (RRMS) Patients Who Were Treatment-Naive or Who 
      Relapsed on Prior Therapy (Poster Session II -- P2.209; April 29; 7:30 
      a.m. EDT) 
 
   -- Alemtuzumab Improves Visual Outcomes vs. Subcutaneous Interferon Beta-1a 
      in Patients With Active Relapsing-Remitting Multiple Sclerosis (RRMS) Who 
      Relapsed on Prior Therapy: Analysis From the CARE-MS II Study (Poster 
      Session III -- P3.158; April 29; 3:00 p.m. EDT; INS 7 Poster Rounds: 
      Emerging Therapeutic Advances in Multiple Sclerosis -- I7-1.010; April 
      30; 4:30 p.m. EDT) 
 
   -- Sustained Improvement in Disability Outcomes with Alemtuzumab in Active 
      Relapsing-Remitting Multiple Sclerosis Patients Who Participated in 
      CARE-MS II: Three-year Follow-up (Poster Session III -- P3.165; April 29; 
      3:00 p.m. EDT) 
 
   -- Lymphocyte Counts Do Not Predict Risk of Subsequent Relapse or Disability 
      Accumulation in Alemtuzumab-Treated Relapsing-Remitting Multiple 
      Sclerosis Patients: An Analysis of the CARE-MS Studies (Poster Session 
      III -- P3.181; April 29; 3:00 p.m. EDT) 
Abstracts are available on the AAN website.
Genzyme Corporate Therapeutic Update
"The Evolving Paradigm: Individualizing MS Care"
When: Tuesday, April 29; 7:00 -- 8:30 p.m. EDT
Location: Sheraton Philadelphia Downtown Hotel, Liberty Ballroom (201 N 17th Street, Philadelphia)
Brain Health Fair
Genzyme is proud to serve as a silver sponsor of this year's Brain Health Fair, taking place on Saturday, April 26. The Brain Health Fair, presented by the American Brain Foundation, the foundation of the American Academy of Neurology, is a free event that is open to the public and designed to help connect patients, families and caregivers affected by neurologic disorders.
About Aubagio(R) (teriflunomide)
Aubagio is approved in the United States, European Union, Australia, Argentina, Brazil, Canada, Chile, Columbia, Mexico, New Zealand, South Korea and Switzerland, with additional marketing applications under review by regulatory authorities globally.
Aubagio is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for Aubagio is not fully understood, it may involve a reduction in the number of activated lymphocytes in the central nervous system (CNS). Aubagio is supported by one of the largest clinical programs of any MS therapy, with more than 5,000 trial participants in 36 countries. Some patients in extension trials have been treated for up to 10 years.
About Lemtrada(TM) (alemtuzumab)
Lemtrada is approved in the European Union, Australia, Brazil, Canada and Mexico. Lemtrada is currently not approved in the United States. Following constructive discussions with the FDA, Genzyme plans to resubmit in the second quarter of 2014 its application seeking U.S. approval of Lemtrada. The resubmission will provide information to specifically address issues previously noted by the FDA in its December 2013 Complete Response Letter. Marketing applications for Lemtrada are also under review in other countries. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients and 5,400 patient-years of follow-up.
Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells. Treatment with alemtuzumab results in the depletion of circulating T and B cells thought to be responsible for the damaging inflammatory process in MS. Alemtuzumab has minimal impact on other immune cells. The acute anti-inflammatory effect of alemtuzumab is immediately followed by the onset of a distinctive pattern of T and B cell repopulation that continues over time, rebalancing the immune system in a way that potentially reduces MS disease activity.
Genzyme holds the worldwide rights to alemtuzumab and has primary responsibility for its development and commercialization in multiple sclerosis. Bayer HealthCare holds the right to co-promote alemtuzumab in MS in the United States. Upon commercialization, Bayer will receive contingent payments based on global sales revenue.
READ About Genzyme, a Sanofi Company

……..


To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------
Donate Now Please - Click here
Thank you    
…………………….
.